| Ytd | 98.17% | |
| 1y | 859.91% |
| Open | 3.06 | Prev Close | 3.04 | Low | 3.00 | High | 3.06 | Mkt Cap | 190.94M |
| Vol | 12.99K | Avg Vol | 678.03K | EPS | -0.21 | P/E | N/A | Forward P/E | -0.47 |
| Beta | 1.83 | Short Ratio | 0.53 | Inst. Own | 20.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.53 | 200-d Avg | 1.74 | 1yr Est | 3.33 |
EQ News
Three-year renewal follows early campaign results that delivered up to 40% increases in average orde
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology in
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammator
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
Leerink Partners analyst Thomas Smith upgrades Equillium (NASDAQ:EQ) from Market Perform to Outpe
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.06) per share which missed the analyst consen
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected appro
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup wit
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
B. Riley Securities analyst William Woods initiates coverage on Equillium (NASDAQ:EQ) with a Buy
Raymond James analyst Martin Auster initiates coverage on Equillium (NASDAQ:EQ) with a Strong Buy
Aberdeen Group plc grew its holdings in Equillium, Inc. (NASDAQ: EQ) by 523.6% in the undefined quar
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Cantor Fitzgerald analyst Emma Nealon initiates coverage on Equillium (NASDAQ:EQ) with a Overweig
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.04) per share which beat the analyst consensu
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected app
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Equillium, Inc. (NASDAQ: EQ - Get Free Report) COO Christine Zedelmayer sold 120,312 shares of the s
Roth Capital analyst Adam Walsh initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceed
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial init
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology in
Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest du
Equillium stock is trading higher Monday after the company announced up to $50 million in financing
Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe au
